Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function

Lucia Mazzolai 1*, Walter Ageno2, Adriano Alatri1, Rupert Bauersachs3,4, Cecilia Becattini5, Marianne Brodmann6, Joseph Emmerich7, Stavros Konstantinides1,8, Guy Meyer†, Saskia Middeldorp9, Manuel Monreal10, Marc Righini11, and Victor Aboyans12

1Division of Angiology, Heart and Vessel Department, Lausanne University Hospital, Chemin de Mont-Païsible 18, CH-1011 Lausanne, Switzerland; 2Department of Medicine and Surgery, University of Insubria, Via Rassu 2, 21100 Varese, Italy; 3Department of Vascular Medicine, Klinikum Darmstadt GmbH, Grafenstraße 9, 64283 Darmstadt, Germany; 4Department of Internal and Cardiovascular Medicine—Stroke Unit, University of Perugia, Perugia, Italy; 5Département of Internal Medicine, Division of Angiology, Medical University Graz, Graz, Austria; 6Department of Vascular Medicine, Groupe Hospitalier Paris Saint-Joseph and University of Paris, Paris, France; 7Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece; 8Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands; 9Department of Internal Medicine, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; 10Division of Angiology and Hemostasis, Department of Internal Medicine, Geneva University Hospital, Geneva, Switzerland; and 11Department of Cardiology, Dupuytren University Hospital and Inserm 1094, Tropical Neuroepidemiology, School of Medicine, 5 avenue martin Luther-King 87042 Limoges, France

Received 19 October 2020; revised 25 February 2021; editorial decision 5 May 2021; accepted 7 May 2021

This consensus document is proposed to clinicians to provide the whole spectrum of deep vein thrombosis management as an update to the 2017 consensus document. New data guiding clinicians in indicating extended anticoagulation, management of patients with cancer, and prevention and management of post-thrombotic syndrome are presented. More data on benefit and safety of non-vitamin K antagonists oral anticoagulants are highlighted, along with the arrival of new antidotes for severe bleeding management.

Keywords
Consensus • Deep vein thrombosis • Ultrasound • Anticoagulation • Diagnosis • Pulmonary embolism • Cancer • Post-thrombotic syndrome • Catheter-directed thrombolysis • Pregnancy • Risk • Compression

* Corresponding author. Tel: +41 21 3140768; +41 795565661, Email: lucia.mazzolai@chuv.ch
†Deceased.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Summary of consensus statements

DVT diagnosis

Revised. Clinical prediction rule (two-level modified Wells score, Supplementary material online, Table S1) should be used to stratify patients with suspected DVT

Revised. ELISA D-dimer or highly sensitive immunoturbidimetric tests should be measured in ‘unlikely’ clinical probability patients to exclude DVT diagnosis

Venous US is recommended as first-line imaging method for DVT diagnosis

Venous CT scan should be reserved to selected patients only

Venous US may be proposed also in case of confirmed PE, for initial reference venous imaging, useful in case of DVT recurrence suspicion or further stratification in selected patients

Venous US may be considered for further severity stratification in selected patients with concomitant suspected PE

Initial and long-term DVT management

Patients with proximal DVT should be anticoagulated for at least 3 months

Patients with isolated distal DVT at high risk of recurrence should be anticoagulated, as for proximal DVT; for those at low risk of recurrence shorter LMWH treatment (4–6 weeks), even at lower anticoagulant doses, or ultrasound surveillance may be considered

In non-cancer patients

• NOACs should be preferred as first-line anticoagulant therapy in absence of contraindications

• New. If a parenteral agent is used, LMWH should be preferred over UFH for the initial treatment

In cancer patients:

• LMWH should be preferred over UFH for initial treatment

• LMWH is recommended over VKA for long-term treatment

• Edoxaban and rivaroxaban should be considered as an alternative to LMWH for initial and long-term treatment in patients without gastrointestinal or urothelial cancer. Caution should be made for any potential drug interaction with anti-cancer therapy

• Apixaban should be considered as an alternative to LMWH for initial and long-term treatment in patients without primary or metastatic brain cancer or acute leukaemia. Caution should be made for any potential drug interaction with anti-cancer therapy

• LMWH is preferred over NOACs for initial and long-term treatment in cancer patients, with unstable clinical situations, such as low platelet count, nausea, and vomiting, and a risk of expected drug interactions with the anti-cancer therapy as well as those undergone surgery involving the upper gastrointestinal tract

New. Anticoagulant choice should include patient’s preference, and may include cost, mode of administration, and monitoring options

Revised. Adjunct catheter-directed thrombolysis should not be routinely performed and be reserved for individual and very severe cases and performed in experienced centres

Primary acute DVT stenting or mechanical thrombus removal alone are not recommended

Revised. Vena cava filters should be considered if anticoagulation is absolutely contraindicated or in case of recurrent VTE event under adequate therapeutic anticoagulation

Revised. In patients with proximal DVT, immediate (<24 h from diagnosis) compression therapy associated with early mobilization and walking exercise may be proposed to relieve acute venous symptoms
Extended management (>first 3 months) of DVT (without PE)

Revised. When deciding for extended anticoagulation, individual risk assessment should be proposed for all DVT patients, also taking into account patients’ preferences, compliance, and impact of long-term DVT complications. For this purpose scores may be helpful in risk stratification

New. In patients at low risk of recurrence (Table 5), anticoagulation discontinuation should be proposed

New. In patients at intermediate risk of recurrence (Table 5), anticoagulation extension should be considered, provided bleeding risk is low

New. Currently, reduced-dose apixaban and rivaroxaban have shown their benefit in patients at intermediate risk of recurrence

New. In patients at high risk or variable higher risk of recurrence (Table 5), anticoagulation should be continued, provided bleeding risk is low

In absence of contraindications, NOACs should be preferred as first-line extended anticoagulant therapy in non-cancer patients, except in patients with antiphospholipid syndrome

New. In patients with antiphospholipid syndrome, anticoagulation extension with VKA is recommended

New. In absence of contraindications, full-dose oral anticoagulants may be proposed in active cancer patients after 6 months treatment

When VKAs are proposed, they should be administered at conventional intensity regimen (INR 2–3)

New. Patients on extended anticoagulation, should be assessed regularly (at least yearly) for patient preference, benefit/risk balance, and PTS development monitoring

At anticoagulation discontinuation, venous US should be performed to establish a baseline comparative exam in case of recurrence

New. Use of elastic compression stocking should be individualized

New. Endovascular recanalization may be considered on an individual base in patients with chronic venous occlusion provided dedicated venous material is used in expert centres

DVT management in special situations

Revised. In case of upper extremity deep vein thrombosis (UEDVT) suspicion, venous US is the first choice imaging test; if negative, CT venography should be performed

Treatment of UEDVT is similar to that of lower limb DVT with regard to anticoagulation

New. In case of catheter-related thrombosis, the catheter may be kept in place if it is functional, well positioned, and non-infected

Revised. For acute (up to 15 days) treatment of cerebral vein thrombosis LMWH should be proposed

Revised. For long-term treatment of cerebral vein thrombosis dabigatran or VKA should be suggested

LMWH are recommended for acute treatment of splanchnic vein thrombosis

New. VKA should be proposed for long-term treatment of splanchnic vein thrombosis

New. LMWH may be proposed for long-term treatment of splanchnic vein thrombosis in selected cases (cirrhosis, solid cancer, or high risk of bleeding)

DVT in pregnancy, oral contraception, and thrombophilia

Revised. Venous US including visualization of iliac veins is recommended as first-line DVT imaging test

During pregnancy, LMWH should be proposed for initial and long-term treatment

Revised. Anticoagulant treatment should be continued until 6 weeks after delivery and at least for 3 months

New. Non-hormonal contraception, a levonorgestrel intrauterine device, the progestogen-only pill, or a subcutaneous progestogen implant are safe with regard to DVT risk

New. Routine anti-Xa monitoring and dose adaptation is not recommended in pregnant patients

New. Testing for thrombophilia should be reserved for situations where results would change management

Introduction

This consensus on diagnosis and management of deep vein thrombosis (DVT) is proposed to clinicians as an update to the 2017 consensus document and a companion paper to the 2019 ESC guidelines on diagnosis and management of pulmonary embolism (PE) in order to provide the whole spectrum of management of patients with venous thromboembolic disease (VTE). Management of DVT has similarities with that of PE, however, many diagnostic and therapeutic features present particularities which have recently been subject to a high flow of new evidence, justifying the need for an update of the previous document, with a timely publication along with the new ESC PE guidelines. Of importance, this document integrates new data guiding clinicians deciding for extended anticoagulation, management of patients with cancer, prevention and management of post-thrombotic syndrome (PTS), management of bleeding during anticoagulation, and management of DVT in pregnancy (including hormone-related DVT and thrombophilia). More data on benefit and security of non-vitamin K antagonists oral
anticoagulants (NOACs) are highlighted, along with the arrival of new antidotes for the management of severe bleeding. On behalf of the two ESC working groups, authors emphasize the multidisciplinary approach for comprehensive management of both aspects of VTE, which may occur in a same patient, simultaneously, or over time. In line with ESC documents, the term NOAC is used instead of direct oral anticoagulant.

Deep vein thrombosis risk factors

Cohort studies indicate that in as much as 50% of DVT no identifiable risk factors are found. Risk factors (Table 1) can be distinguished as major (strong association with index DVT; likely responsible of index event), intermediate (moderate association with index DVT, probably responsible of index event), or minor (weak association with index VTE; might partly explain index event). Categorization of index event is important for determining recurrence risk and patient management. An emerging thrombotic risk factor is represented by the coronavirus disease 2019 (COVID-19). COVID-19 infection often results in a hypercoagulable state with high incidence of venous and arterial thromboembolic events, frequently despite antithrombotic prophylaxis. A recent meta-analysis evaluated 48 observational studies reporting VTE incidence among hospitalized patients for COVID-19. Based on a pooled sample of 18,093 patients, overall VTE incidence was 17.0%, with 7.1% in patients admitted to the ward and 27.9% in patients admitted to the intensive care unit. Therefore, hospitalized patients with COVID-19 infection should be considered at intermediate-high risk for VTE.

Deep vein thrombosis diagnosis

There have been no major changes in this section from the 2017 version. Figure 1 summarizes diagnostic strategies in case of DVT suspicion. In case of concomitant signs suspect for PE, diagnostic strategies should follow the 2019 ESC guidelines on PE diagnosis and management.

Initial (first days) and long-term (first 3 months) deep vein thrombosis management

Three phases characterize DVT management (Figure 2): initial (first days), long-term (first 3 months), and extended (following the initial 3-month treatment period). Current anticoagulation strategies differ when DVT is diagnosed in cancer patients as compared to those without active cancer.

Table 1 Deep vein thrombosis risk factors

| Risk factors | Strong risk factors (OR ≥ 10) |
|--------------|-----------------------------|
|              | Major surgery (orthopaedic and neurological)/major trauma |
|              | Recent (<3 months) hospitalization for acute heart disease |
|              | Prior venous thromboembolism |
|              | Antiphospholipid syndrome |
|              | Active cancer (depends on type and stage)/chemotherapy |
| Moderate risk factors (OR 2–9) |
|              | Arthroscopic knee surgery |
|              | Venous catheters |
|              | Oral contraception/hormone replacement therapy/in vitro fertilization (depends on dose and type of hormone) |
|              | Pregnancy or postpartum period |
|              | Inflammatory and autoimmune diseases |
|              | Infections |
|              | Active cancer (depends on type and stage)/chemotherapy |
|              | Congestive heart or respiratory failure |
|              | Genetic thrombophilia |
|              | Superficial vein thrombosis (>3 cm from SFJ or PJ and >5 cm length) |
|              | Stroke with residual hemiparesis/hemiplegia |
| Weak risk factors (OR < 2) |
|              | Bed rest (>3 days)/immobility (prolonged sitting position, i.e. travel) |
|              | Age |
|              | Obesity |
|              | Superficial vein thrombosis |
|              | Varicose veins/chronic vein insufficiency |
|              | Laparoscopic surgery |

OR, odds ratio.
Anticoagulation in non-cancer patients

For anticoagulation in non-cancer patients, as already reported in the 2017 edition, NOACs should be preferred as first-line anticoagulant therapy in the absence of contraindication. However, for patients with COVID-19 infection, particularly in hospitalized patients NOACs should be avoided and parenteral anticoagulation, with Unfractionated Heparin (UFH) or low-molecular-weight heparin (LMWH), is preferred because of potential high risk of rapid clinical deterioration with multi-organ failure. In addition, concomitant therapy with antiviral agents, immunomodulatory agents, or other investigational treatment have potential drug–drug interactions with NOACs via CYP3A4 and P-gp pathways. Conversely, following the acute phase or in the post-hospital discharge setting, NOACs remain the first choice, in the absence of drug–drug interaction.

Anticoagulation in cancer patients

LMWH appears possibly superior to UFH in the initial phase (first 5–10 days) of VTE treatment in patients with cancer. For the long-term treatment, the CLOT trial represents a cornerstone, showing for the first time that LMWH is more effective than VKA in reducing risk of recurrent VTE in cancer patients [risk ratio (RR) 0.51, 95% confidence interval (CI) 0.33–0.79] without significant differences in major bleeding risk. Several meta-analyses confirmed the superiority of LMWH with respect to VKA. Concerning NOACs, a meta-analysis of randomized clinical trials comparing efficacy and safety of long-term NOACs with conventional VKA anticoagulation was performed in a subgroup of patients with cancer. Overall, no reduction of VTE recurrence [odds ratio (OR) 0.63, 95% CI 0.37–1.10] and major bleeding (OR 0.77, 95% CI 0.41–1.44) were observed in patients receiving NOACs. Conversely, a second meta-analysis showed statistically significant reduction for VTE recurrence VKA (RR 0.65, 95% CI 0.45–0.95) and major bleeding (RR 0.58, 95% CI 0.45–0.95) with NOACs against VKA. However, baseline characteristics of cancer patients in these trials were not comparable to those in specific cancer studies. Also, the comparator, VKA, was not considered adequate, as LMWH was the recommended long-term treatment for cancer patients.

Four recent randomized clinical trials compared efficacy and safety of NOACs vs. LMWH in cancer patients. Hokusai cancer study compared edoxaban to dalteparin for the long-term treatment (12 months) in cancer patients (98% with active cancer) with acute:

---

**Figure 1** Proposed algorithm for deep vein thrombosis assessment and management. AC, anticoagulation; DVT, deep vein thrombosis; IDDVT, isolated distal DVT; LMWH, low-molecular-weight heparin; NOAC, non-vitamin K antagonists oral anticoagulant; PTS, post-thrombotic syndrome; US, ultrasound.
VTE; >50% of patients had metastatic disease, and >70% received anti-cancer treatment within previous 4 weeks before inclusion. SELECT-D was a pilot open-label trial in patients with DVT, comparing rivaroxaban with dalteparin for a total of 6 months (Table 2). In both studies, NOACs were at least not inferior to LMWH for VTE recurrence (rivaroxaban showed superiority) but showed significantly increased bleeding events although primarily confined to patients with gastrointestinal cancer.14,15 Two clinical trials compared apixaban vs. dalteparin.16,17 In the largest one, the Caravaggio study, ~97% of patients had active cancer; >65% had metastatic disease; and >60% received anti-cancer treatment at time of enrolment (85% within previous 6 months before inclusion). Apixaban showed non-inferiority compared to dalteparin for VTE recurrence (rivaroxaban showed superiority) but showed significantly increased bleeding events although primarily confined to patients with gastrointestinal cancer.14,15

Two clinical trials compared apixaban vs. dalteparin.16,17 In the largest one, the Caravaggio study, ~97% of patients had active cancer; >65% had metastatic disease; and >60% received anti-cancer treatment at time of enrolment (85% within previous 6 months before inclusion). Apixaban showed non-inferiority compared to dalteparin for VTE recurrence at 6 months [5.6% vs. 7.9%, hazard ratio (HR) 0.63 (95% CI 0.37–1.07); P < 0.001 for non-inferiority]. Interestingly, and contrary to previous studies, incidence of major bleeding and clinically relevant non-major bleeding events were similar in both groups (HR 0.82; 95% CI 0.40–1.69 and HR 1.42; 95% CI 0.88–2.30, respectively) (Table 2). Notably, a bleeding analysis of Caravaggio showed that the gastrointestinal bleeding risk is increased (even with LMWH) if the gastrointestinal cancer is not resected.18 In addition, patients with primary brain tumours, intracerebral metastases, or acute leukaemia were excluded from study (but not in Hokusai and Select-D).17

Patients with cancer experience a high rate of VTE recurrence in spite of anticoagulation. One-year recurrence rate of 20% observed with VKA could almost be reduced by half with long-term administration of LMWH. Based on available evidence for edoxaban or rivaroxaban, the use of NOACs may lead to further VTE recurrences reduction, but at higher risk of major bleeding, particularly in patients with gastrointestinal cancers. Apixaban was at least as safe and as effective as LMWH. However, its use cannot be recommended in patients with primary or metastatic brain cancer or acute leukaemia as these patients were not included in the Caravaggio study. LMWH should be preferred in patients in whom drug–drug interaction is a concern and in those who have undergone surgery involving the upper gastrointestinal tract because absorption of all NOACs occurs in the stomach or proximal small bowel.19 LMWH should also be preferred in patients with severe thrombocytopenia as well as nausea and vomiting. To summarize, anticoagulation should be individualized based on patient’s characteristics and preferences as well as cancer’s characteristics and treatment.

**Anticoagulation in isolated distal deep vein thrombosis**

Whether all isolated distal DVT (IDDVT) should be treated with anticoagulation remains debated. Compared to proximal DVT, risk of VTE recurrence for IDDVT is lower in low-risk patients and similar in high-risk patients.20,21 The CACTUS trial showed that in low-risk patients with IDDVT, rate of symptomatic VTE at 42 days was not different between LMWH and placebo (3.3% vs. 5.4%, P = 0.54); bleeding occurred more frequently in the LMWH group (4% vs. 0%, P = 0.03).22 Management of IDDVT should be therefore individualized (Figures 2 and 3). Patients at high risk (Table 4) of VTE may be treated with full-dose anticoagulants for at least 3 months, similar to proximal DVTs.23,24 Longer LMWH treatment (4–6 weeks), even at lower doses, or ultrasound (US) surveillance may be effective and safe in low-risk patients (Table 3).23,25,26 In the absence of clinical trials, recent results from two prospective registries suggested efficacy and safety of NOACs in patients with IDDVT.27,28

**Additional therapeutic options**

**Thrombolysis/thrombectomy**

The CAVENT randomized controlled study found modest advantage of catheter-directed in situ thrombolysis (CDT) plus anticoagulation over anticoagulation alone with regard to occurrence of PTS up to
2 years (37% vs. 55%, \(P = 0.047\)); no difference in quality of life was observed.\(^{29}\) However, the large randomized ATTRACT trial\(^ {30}\) showed no significant difference in PTS occurrence rates in patients treated with adjuvant CDT (47% vs. 48% in the control group; \(P = 0.56\)). CDT led to more major bleeding within 10 days (1.7% vs. 0.3% of patients, \(P = 0.049\)); a non-statistically significant difference in recurrent VTE was seen over 24-month follow-up (12% vs. 8%, \(P = 0.09\)). Patients treated with CDT had lower rates of moderate-

---

**Table 2  Randomized clinical trials comparing non-vitamin K antagonists oral anticoagulants vs. low-molecular-weight heparin in cancer patients**

| Study                | Number of patients | Duration therapy | Primary endpoint                        | Secondary endpoint |
|----------------------|--------------------|------------------|-----------------------------------------|--------------------|
| Hokusai cancer\(^ {14}\) | Overall: 1046      | Edoxaban: 211 days (IQR 76–357) Dalteparin: 184 days (IQR 85–341) | Recurrent VTE or MB at 12 months (edoxaban vs. dalteparin) 12.8% vs. 13.5% HR 0.97 (0.70–1.36) (\(P = 0.006\) for non-inferiority) | VTE recurrence (edoxaban vs. dalteparin) 7.9% vs. 11.3% HR 0.71 (0.48–1.06) \(P = 0.09\) MB 6.9% vs. 4.0% HR 1.77 (1.03–3.04) \(P = 0.04\) Clinically relevant non-MB 14.6% vs. 11.1% HR 1.38 (0.98–1.94) |
| Select-D\(^ {15}\)     | Overall: 406       | Edoxaban: 211 days (IQR 76–357) Dalteparin: 184 days (IQR 85–341) | VTE recurrence at 6 months (edoxaban vs. dalteparin) 4% vs. 11% HR 0.43 (0.19–0.99) | VTE recurrence (edoxaban vs. dalteparin) 7.9% vs. 11.3% HR 0.71 (0.48–1.06) \(P = 0.09\) MB 6.9% vs. 4.0% HR 1.77 (1.03–3.04) \(P = 0.04\) Clinically relevant non-MB 14.6% vs. 11.1% HR 1.38 (0.98–1.94) |
| Caravaggio\(^ {17}\)   | Overall: 1155      | Edoxaban: 178 days (IQR 106–183) Dalteparin: 175 days (IQR 79–183) | VTE recurrence at 6 months (edoxaban vs. dalteparin) 5.6% vs. 7.9% HR 0.63 (0.37–1.07) \(P < 0.001\) for non-inferiority | VTE recurrence (edoxaban vs. dalteparin) 7.9% vs. 11.3% HR 0.71 (0.48–1.06) \(P = 0.09\) MB 6.9% vs. 4.0% HR 1.77 (1.03–3.04) \(P = 0.04\) Clinically relevant non-MB 14.6% vs. 11.1% HR 1.38 (0.98–1.94) |

HR, hazard ratio; IQR, interquartile range; MB, major bleeding; VTE, venous thromboembolism.

---

**Figure 3** Shift of deep vein thrombosis management: from ‘one fits all’ to an ‘individual patient’ approach. DVT, deep vein thrombosis; NOAC, non-vitamin K antagonists oral anticoagulant; PTS, post-thrombotic syndrome; VKA, vitamin K antagonist; VTE, venous thromboembolism.
to-severe PTS (18% vs. 24%, P = 0.04) during the follow-up. PTS severity scores were lower in the CDT group at 6, 12, 18, and 24 months (P < 0.01 for the comparison of the Villalta scores at each time point). However, improvement in quality of life did not differ significantly between groups. A subgroup analysis of acute iliofemoral thrombosis showed similar results, except for greater improvement in venous disease-specific quality of life at 24 months. A third study, the CAVA trial, showed that additional US-accelerated catheter-directed thrombolysis does not change PTS risk 1 year after acute iliofemoral DVT compared with standard therapy alone. Incidence of PTS was 29% vs. 35% for additional thrombolysis and standard treatment, respectively (OR 0.75, 95% CI 0.38–1.50; P = 0.42). Major bleeding occurred solely in the CDT group (5% vs. 0%) most within 10 days. A post hoc analysis showed significant reduction in symptom severity and improvement of generic quality of life according to the EQ-5D. To note, several baseline characteristics in the CDT group of the three studies were different. Patients in CAVA trial were younger (median age 49 years) than in ATTRACT and CAVENT (52 and 53, respectively). In addition, CAVA trial included >90% of iliofemoral thrombosis (vs. 58% and 42%) and 70% of DVTs were located in the left side (vs. 62% and 60%). Finally, in CAVA trial, showed that additional US-accelerated catheter-directed thrombolysis does not change PTS risk 1 year after acute iliofemoral DVT compared with standard therapy alone.

Extended phase management (beyond first 3 months)

Anticoagulation beyond initial 3-month phase should be decided after careful assessment of individual recurrence risk, bleeding, patient compliance and preference, and impact of long-term DVT complications (Figure 3 and Table 4).

Recurrence is higher in the first year after treatment discontinuation, it reduces over time but never falls to zero. Recurrent VTE is a DVT in ~60% and 40% of patients after index DVT or PE, respectively. Once anticoagulation is stopped, VTE recurrence risk differs based on features of index event, it is more than doubled (annual rate > 8%, Table 4) in patients without identifiable risk factors vs. those in whom a risk (‘provoking’) factor is identified. Traditionally, discontinuation of anticoagulation was considered appropriate if risk of recurrence is <5% at 1 year, and <15% at 5 years. Prolonging anticoagulation reduces recurrence by 80–90%, but exposes to risk of unpredictable bleeding complications. Risk of major bleeding associated with extended NOACs treatment, especially when used in patients at low risk of bleeding and at reduced doses, is lower than that reported with VKA. This could decrease the recurrence threshold deemed necessary to continue anticoagulation.

Three clinical prediction rules have been proposed to detect low recurrence risk patients; however, their role is debated in the era of NOACs with low bleeding risk (Table 5). Annualized major bleeding rates in patients continuing anticoagulation can be as high as 3–4%. No bleeding risk score showed sufficient predictive accuracy or had sufficient validation to be recommended in routine clinical practice. They can serve to identify treatable/reversible bleeding risk factors, and determine frequency of follow-up. New scores for patients on NOACs have recently been proposed (Supplementary material online, Table S2). Factors associated with high bleeding risk are, among others, advanced age, cancer, renal or liver insufficiency,
concomitant antithrombotic drugs, and history of previous major bleeding. A summary of data on anticoagulant therapies used for extended management is presented in Supplementary material online. Two studies investigated aspirin 100 mg vs. placebo in patients with VTE without identifiable risk factors who completed initial anticoagulation treatment. Pooled HR for VTE recurrence was 0.68 (95% CI 0.51–0.90) and 1.24 (95% CI 0.46–3.33) for major bleeding. Thus, aspirin reduces rate of recurrences to a lesser extent than oral anticoagulants and is associated with similar bleeding rate as rivaroxaban 10 mg o.d. Therefore, use of aspirin is not indicated in the era of NOACs.

### Duration of anticoagulation in non-cancer and cancer patients

For proximal DVT (with or without concomitant PE), 3-month anticoagulation is the best option if risk of recurrence is low (i.e. major transient/reversible risk factors; Table 4). Provided bleeding risk is low, indefinite anticoagulation is the best option for patients with high risk of recurrence (i.e. multiple VTE episodes in absence of a major transient or reversible factor; VTE familial history, those with major thrombophilia; Table 4). Patients with DVT without identified risk factors and low bleeding risk are candidates for extended anticoagulation beyond the initial 3 months. Dichotomizing VTE into provoked and unprovoked categories to guide treatment appears simple, but studies showed that patients with provoked VTE are at higher recurrence risk compared to those without VTE history. Also, recent trials have not shown a clear difference regarding benefit of extended anticoagulation according to the provoked/unprovoked status. Therefore, optimal DVT management requires a more nuanced approach (Figure 3). In absence of contraindications, NOACs should be preferred as first-line extended anticoagulant therapy in non-cancer patients, except in patients with antiphospholipid syndrome where only VKA is recommended. In patients at intermediate risk of recurrence, two RCTs comparing full and reduced dose of apixaban with placebo have shown that reduced doses were as effective as full dose with comparable bleeding risk as placebo or aspirin. Due to high recurrence risk, patients with cancer should be individually evaluated with regard to anticoagulation duration depending on their specific circumstances.

### Table 4 Estimated risk of venous thromboembolic disease recurrence after anticoagulants discontinuation in proximal deep vein thrombosis

| Estimated risk of recurrence | Risk factor category for index DVT | Examples |
|-----------------------------|-----------------------------------|----------|
| Low (<3%/year)              | Major transient/reversible risk factors | Surgery with general anaesthesia for longer than 30 min |
|                             |                                    | Confined to bed in hospital (only ‘bathroom privileges’) for at least 3 days due to an acute illness, or acute exacerbation of a chronic illness |
|                             |                                    | Trauma with fractures |
| Intermediate (3–8%/year)    | Minor transient/reversible risk factors | Minor surgery (general anaesthesia for <30 min) |
|                             |                                    | Admission to hospital for <3 days with an acute illness |
|                             |                                    | Obesity (high body mass index) |
|                             |                                    | Ongoing oestrogen therapy |
|                             |                                    | Pregnancy or puerperium |
|                             |                                    | Confined to bed out of hospital for at least 3 days with an acute illness |
|                             |                                    | Leg injury (without fracture) associated with reduced mobility for at least 3 days |
|                             |                                    | Long-haul flight |
| Non-malignant persistent risk factors | Inflammatory bowel and active autoimmune diseases (risk may change depending on activity and treatment)a |
| High (>8%/year)             | Major persistent risk factors | One or more previous episodes of VTE in absence of a major transient or reversible factor |
|                             |                                    | Active cancer |
|                             |                                    | Antiphospholipid antibody syndrome |
|                             |                                    | Major hereditary thrombophiliab |
|                             |                                    | Strong family historyc |
| Variable                    | First episode with no identifiable risk factors | Higher recurrence risk: men, proximal DVT, concomitant PE, high D-dimers at anticoagulation discontinuation, age |

DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolic disease.

aAlso at increased bleeding risk.

bConfirmed antithrombin, protein C or protein S deficiency, homozygous factor V Leiden, homozygous prothrombin G20210A mutation, double heterozygous.

cFirst-degree relative with personal history of proximal DVT or PE.
### Table 5  Clinical prediction models for venous thromboembolism recurrence after first episode of venous thromboembolic disease

| Prediction model | Parameters | Points | Risk categories | Population studied | Low-risk recurrent |
|------------------|------------|--------|-----------------|-------------------|-------------------|
| **VIENNA"**\(^{48-50}\) | • D-dimer (after stopping AC) • Male sex • VTE location (distal DVT, proximal DVT, PE) | NA | Nomogram | Unprovoked VTE | 4.4% (95% CI 2.7–6.2) |
| **HERDOO-2"**\(^{51,52}\) | • Abnormal D-dimer (before stopping AC) • Age ≥ 65 years • BMI > 30 • Hyperpigmentation, oedema and redness | 11 | | | |
| **DASH"**\(^{53,54}\) | • Abnormal D-dimer (after stopping AC) • Age < 50 years • Men • Hormonal therapy | 1 | | | |
| **DAMOVES"**\(^{55,56}\) | • Abnormal D-dimer • Age • Sex • Obesity • Factor VIII • Genetic thrombophilia • Varicose veins | NA | Nomogram | Unprovoked VTE | 2.9% (95% CI 2.13–4.35) |

AC, anticoagulation; BMI, body mass index; CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolic disease.
on cancer type, staging, activity, chemotherapy, life expectancy, etc. as well based on presence of active cancer or remission state (Figure 3).25 Risk benefit ratio of continuing anticoagulation needs to be period-ically re-assessed, as risk for recurrence and bleeding may vary over time.71–73 Prolonged anticoagulation may consist of oral antico-agulants. VTE recurrence in cancer patients on VKA (with adequate INR) requires changing to LMWH. Recurrence on LMWH may be managed by increasing dosing or opting for vena cava filter placement in selected patients.25 Notably, data about prolonged treatment with NOAC in DVT cancer patients are very limited. The only Hokusai study evaluated anticoagulation with NOAC up to 12 months.74

Prevention and management of post-thrombotic syndrome
PTS is the most frequent chronic DVT complication, occurring in 30–50% of patients within 2 years after proximal DVT.75 In 5–10% of cases, PTS is severe.75

Pathophysiology of PTS is yet not completely elucidated. Previous ipsilateral DVT, iliofemoral location, and residual veins obstruction are most significant PTS risk factors.76 Three different clinical prediction models were recently proposed.77–79 Similarly, there is no gold standard for PTS diagnosis. The Villalta score is the most used tool for diagnosis and treatment evaluation (Supplementary material online, Table S3).80 Standard and effective management for PTS prevention and treatment is lacking, a shift from a ‘one fit for all’ model to a personalized one is warranted (Figure 3). For decades, elastic compression stockings has been the mainstay for PTS management, based on two open-label randomized controlled trials both showing a 50% relative risk reduction in PTS development.81,82 In the randomized SOX trial compression stockings were compared to placebo stockings and no difference in PTS was observed. Discrepancy may be explained by the compliance definition (only 56% of patients wearing stockings ≥3 days/week), lack of patient education, and low rate of immediate (<24 h post-DVT diagnosis) compression.83 A recent Bayesian meta-analysis showed that it is probable to observe a pro- tective effect of compression stockings when applied in the acute set-ting of a DVT.84 Two recent clinical trials showed that good compliance (wearing ECS for at least 6 days/week) and high adherence (>80%) is associated with significantly lower PTS inci-dence.85,86 They also suggest that duration of elastic compression stocking use could be individualized (Figure 3).

PTS pathophysiology relies on the principle of outflow obstruction, partly caused by venous hypertension, leading to valvular dam-age and venous reflux or insufficiency. Recent technical develop-ments and new dedicated venous stent techniques allow recanalizing even complex chronic venous outflow obstructions. Although first in man safety and efficacy data are promising, well-con-ducted trials are needed.87–89

Follow-up
Patients should be followed to avoid risk of recurrence as well as DVT-related and anticoagulation-related complications, to review treatment, lab values, and patient information. While on anticoagula-tion a yearly assessment is indicated. Development of conditions requiring anticoagulation adjustment should be monitored (e.g. renal insufficiency, pregnancy, weight loss, severe hypertension).

Treatment compliance as well as benefit/risk balance should be assessed. Development of PTS should be evaluated. Venous US assessment, prior to anticoagulation discontinuation, is useful in deter-mining baseline residual vein thrombosis not to drive anticoagulant treatment duration, but to differentiate between old and new throm-bosis in case of new symptoms. Following anticoagulation discontinu-ation, information should be given regarding future high thrombotic risk situations.90

Special situations

Deep vein thrombosis in pregnancy, oral contraception, and thrombophilia
Pregnancy increases VTE risk by four- to five-fold.91 VTE risk factors are listed in Table 6. Femoral and/or (isolated) iliac vein thrombosis occurs more often in pregnant than in non-pregnant patients, mainly on the left side due to anatomical reasons. Women have a 42% risk of PTS and 7% of severe PTS after pregnancy-related DVT.92 Validity of DVT clinical prediction rules in pregnancy has not yet been tested prospectively.77 The LEFt clinical score was proposed;93 however, it remains to be prospectively validated, and integrated into a standar-dized diagnostic strategy.95 Although D-dimers increase during pregnancy, normal values exclude VTE with likelihood similar to non-pregnant women.96 Venous US is the primary imaging test and should specifically include imaging of iliac veins.97 If venous US is negative but clinical suspicion high, testing should be repeated at 7–10 days.96,97 Rarely, computed tomography (CT) (or magnetic resonance imaging) venography may be considered.98 Treatment consists of therapeutic dose heparin (no placenta crossing and not significantly found in breast milk) with a preference of LMWH over UFH.97 Anti-Xa moni-toring and dose adaptation is not recommended routinely, but may be considered in women of extreme body weight or renal insuffi-ciency.97 Whether initial full-dose anticoagulation can be reduced for secondary prevention during ongoing pregnancy has never been investigated.98 CDT therapy has not been investigated in pregnant women and should not be added to anticoagulation.97 Evidence is insuffi-cient to recommend o.d. over b.i.d. LMWH, but o.d. is more pa-tient friendly. Peripartum management should be approached by a multidisciplinary team and there is large variation in practice with re-gard to temporary interruption of LMWH, scheduled delivery, and access to neuraxial anaesthesia.97,98 Anticoagulation should be con-tinued for at least 6 weeks postpartum and until at least a total of 3 months treatment.97 In breastfeeding women, LMWH can be con-tinued for the remainder of the treatment period or be switched to VKA, which is safe as well.98 In this case, small vitamin K doses (1 mg/ week) should be given to the breast-fed newborn. NOACs are contraindicated in pregnancy/lactation in the absence of safety data. Use of combined oral contraceptives (OC) increases VTE risk, strongest during the first months but remaining three- to eight-fold increased as compared to non-users.99 Presence of thrombophilia further increases risk of hormone-related VTE, sometimes in a multi-plicative way.100 Risk of recurrent VTE in women with hormone-associated VTE is lower than in those with an unprovoked event (HR 0.5, 95% CI 0.3–0.8).101 Hence, 3 months treatment is adequate in most women. OC can be used without increasing recurrence risk if
Therapeutic anticoagulants are used concomitantly. However, increased risk of DVT persists up to 3 months following OC discontinuation warranting use of low-VTE risk contraception as alternative.

Whether or not to test for thrombophilia is a recurring clinical question in patients with DVT. Testing should be reserved for situations where results would change management (e.g., antiphospholipid antibodies, homozygous mutation for factor V or II, severe composite thrombophilia) based on a patient-specific assessment.

### Upper extremities deep vein thrombosis

Upper extremities DVT (UEDVT) accounts for 10% of all DVTs with an annual incidence of 0.4–1.0/10,000 persons. Incidence rises because of increasing use of central venous catheters, cardiac pacemakers, and defibrillators. Complications are similar, although less frequent, to those of lower limb DVT. About 20–30% of UEDVT are primary comprising those caused by anatomic abnormalities or following sustained physical efforts. Secondary DVT include venous catheter- and devices-related complications, cancer, pregnancy, and recent arm/shoulder surgery or trauma. Most common clinical presentation includes pain, swelling, and skin discoloration.

A clinical decision score (Constans score) has been proposed (Supplementary material online). D-Dimer showed good negative predictive value in symptomatic DVT. Venous US is the first choice exam for diagnosis. A diagnostic algorithm, using Constan score, D-dimer, and Venous US was proposed. Contrast-, CT-, and MR-venography are not recommended for diagnosis but limited to unresolved selected cases. Anticoagulation is similar to that of lower limb DVT.

### Uncommon deep vein thrombosis localizations

Splanchnic DVT has been dealt with in the 2017 consensus with no major changes. Concerning cerebral vein thrombosis (CVT), a randomized clinical trial evaluated efficacy and safety of NOAC in 120 patients with CVT. Patients received therapeutic dose of dabigatran (150 mg bid) or adjusted dose of VKA for 24 weeks, after an initial period of 5–15 days with LMWH or UFH. The study found no difference between groups with respect to recurrent VTE and bleeding suggesting that both drugs may be safe and effective in CVT patients. A second study, evaluating efficacy and safety of rivaroxaban in patients with CVT is currently ongoing.

An international, multicentre, prospective registry evaluating the use of NOACs for treating venous thrombosis in unusual sites is currently ongoing as well as a study evaluating safety and efficacy of rivaroxaban in patients with acute splanchnic vein thrombosis without liver cirrhosis.

### Management of bleeding during anticoagulation

Patients treated with VKAs presenting with severe major bleeding should receive intravenous vitamin K and prothrombin complex concentrates (PCCs) to rapidly reverse anticoagulation. In patients treated with NOACs, idarucizumab is the specific reversal agent currently available in Europe for direct factor IIa inhibitor dabigatran. Following the results of the REVERSE-AD trial, this humanized monoclonal antibody is approved for reversal of dabigatran etexilate in patients with major, life-threatening bleeding, and in patients requiring urgent invasive procedures. Reversal agent for direct factor Xa inhibitors is andexanet alfa, a human recombinant factor Xa variant currently approved in the USA by FDA and in Europe by EMA for patients with acute major bleeding. In the ANNEXA4 trial, anti-factor Xa activity of both apixaban and rivaroxaban was reduced by >90% after administering a bolus of andexanet followed by a 2-h infusion. In case of reversal agent unavailability, patients treated with direct factor Xa inhibitors and life-threatening bleeding should receive PCCs. No data about efficacy and safety of tranexamic acid in patients treated with direct factor Xa inhibitors and life-threatening bleeding are currently available.

### Venous thromboembolism during electrophysiology procedures

Femoral veins are the elective route for cardiac catheterization during electrophysiology procedures. However, limited data exist on the VTE risk after such procedures. In a recent systematic review, the pooled incidence rates for DVT after non-AF and AF procedures were 0.24% (95% CI 0.08–0.39%) and 0% (95% CI 0–0.0003%), respectively. The lower rates for the latter are plausible linked to the systematic use of anticoagulation during this procedure, with in turn, more frequent significant haematomas in AF (1%) than non-AF (0.3%) ablations. Indeed, recent joint consensus document (including EHRA) supports the maintenance of oral anticoagulants (if already under) during the intervention, the use of per-procedural heparin.
and anticoagulation in the post-operative period.\textsuperscript{120} In other procedures, especially in the right-sided chambers not requiring anticoagulation, the use of bolus of heparin during the procedure is optional and differs largely by centres.\textsuperscript{121,122} Further studies are necessary to balance the thrombotic vs. bleeding risk in this setting.

Asymptomatic DVT can be documented up to 20% of cases,\textsuperscript{119} but its clinical significance is unclear because of the major contrast and anticoagulation in the post-operative period.\textsuperscript{120} In other procedures, especially in the right-sided chambers not requiring anticoagulation, the use of bolus of heparin during the procedure is optional and differs largely by centres.\textsuperscript{121,122} Further studies are necessary to balance the thrombotic vs. bleeding risk in this setting.

### Supplementary material

Supplementary material is available at European Journal of Preventive Cardiology online.

**Conflict of interest:** None declared.

### References

1. Mazzolai L, Abayans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, Brekelmans MPA, Buller HR, Elias A, Farge D, Konstantinides S, Palareti G, Prandoni P, Righini M, Torbicki A, Vlachopoulos C, Brodmann M. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. *Eur Heart J* 2018;39:4208–4218.

2. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola V-P, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lanket M, Lorusso R, Mazzolai L, Menegus N, Nil Aine F, Prandoni P, Prati D, Przybyłowski P, Righini M, Torbicki A, Van Belle E, Zamaroano JL. ESC scientific document group. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). *Eur Heart J* 2020;41:543–603.

3. Hork AT. The epidemiology of venous thromboembolism in the community: implications for prevention and management. *J Thromb Thrombolysis* 2006;21:23–29.

4. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. *Lancet* 2003;362:523–526.

5. Snyeppooulos AC, Weitz JJ. Hospitalized COVID-19 patients and venous thromboembolism: a perfect storm. *Circulation* 2020;142:129–132.

6. Jiménez D, García-Sanchez A, Rali P, Muriel A, Bidele B, Ruiz-Artacho P, Le Mao R, Rodríguez C, Hunt BJ, Monreal M. Incidence of venous thromboembolism and bleeding among hospitalized patients with COVID-19: a systematic review and meta-analysis. *Chest* 2021;159:1182–1196.

7. Roberton L, Jones LE. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. *Cochrane Database Syst Rev* 2017;2:CD001100.

8. Halkoui MB, Kahale LA, Tsaolakian IG, Matar CF, Yosuico VE, Terrenato I, Sperati F, Barba M, Yosuico VE, Schünemann H, Akli EA. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. *Cochrane Database Syst Rev* 2018;1:CD016649.

9. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, 9. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, 10. Galanaud JP, Sevestre MA, Peron G, Genty C, Richelet S, Kahn SR, Boulon C, Terrasse H, Quere I, Bosson JL. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study. *J Thromb Haemost* 2017;15:907–916.

10. Valerio L, Ambaglio C, Barone M, Ciola M, Konstantinides SV, Mahdipour SH, Picchi C, Piresca C, Trinchero A, Barco S. Recurrence risk after first symptomatic distal versus proximal deep vein thrombosis according to baseline risk factors. *Thromb Haemost* 2020;123:58–63.

11. Righini M, Galanaud JP, Guerneville H, Bristot D, Diard A, Fasse P, Barreiller MT, Hamel-Denas C, Juras P, Pichot O, Martin M, Mazzolai L, Chouquet E, Accassa S, Robert-Ebadi H, Carrier M, Le Gal G, Mercillod B, Laroche JP, Bounameaux H, Perrier A, Kahn SR, Quere I. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. *Lancet Haematol* 2016;3:e556–e562.

12. Righini M, Galanaud JP, Guerneville H, Bristot D, Diard A, Fasse P, Barreiller MT, Hamel-Denas C, Juras P, Pichot O, Martin M, Mazzolai L, Chouquet E, Accassa S, Robert-Ebadi H, Carrier M, Le Gal G, Mercillod B, Laroche JP, Bounameaux H, Perrier A, Kahn SR, Quere I. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. *Lancet Haematol* 2016;3:e556–e562.

13. Righini M, Galanaud JP, Guerneville H, Bristot D, Diard A, Fasse P, Barreiller MT, Hamel-Denas C, Juras P, Pichot O, Martin M, Mazzolai L, Chouquet E, Accassa S, Robert-Ebadi H, Carrier M, Le Gal G, Mercillod B, Laroche JP, Bounameaux H, Perrier A, Kahn SR, Quere I. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. *Lancet Haematol* 2016;3:e556–e562.

14. Righini M, Galanaud JP, Guerneville H, Bristot D, Diard A, Fasse P, Barreiller MT, Hamel-Denas C, Juras P, Pichot O, Martin M, Mazzolai L, Chouquet E, Accassa S, Robert-Ebadi H, Carrier M, Le Gal G, Mercillod B, Laroche JP, Bounameaux H, Perrier A, Kahn SR, Quere I. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. *Lancet Haematol* 2016;3:e556–e562.

15. Righini M, Galanaud JP, Guerneville H, Bristot D, Diard A, Fasse P, Barreiller MT, Hamel-Denas C, Juras P, Pichot O, Martin M, Mazzolai L, Chouquet E, Accassa S, Robert-Ebadi H, Carrier M, Le Gal G, Mercillod B, Laroche JP, Bounameaux H, Perrier A, Kahn SR, Quere I. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. *Lancet Haematol* 2016;3:e556–e562.
thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379: 31–38.

30. Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, Magruder E, Razavi MK, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Duncan JR, Nietert P, Derfler MC, Filion M, Gu CS, Kee S, Schneider J, Saad N, Blinder M, Moore S, Sacks D, Rundback J, García M, Randan V, VanderWoude E, Marques V, Keanon C. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med 2017; 377: 2240–2252.

31. Comerota AJ, Keanon C, Gu CS, Julian JA, Goldhaber SZ, Kahn SR, Jaff MR, Razavi MK, Kindzelski AL, Bashir P, Patel P, Sharafuddin M, Schlau M, Saad NW, Xu Z, Holfeld K, M. Vedantham S for the ATTRACT Trial Investigators. Endovascular thrombolysis for acute iliofemoral deep vein thrombosis. Circulation 2019; 139: 1162–1173.

32. Notten P, ten Cate-Hoek AJ, Arnoldussen C, Strijkers RH, de Smet A, J. Tietema A. MI, Velshchikov VM, Middeldorp S, Palareti G, Poli D, Tait RC, Kyle PA. Risk of recurrence after a first unprovoked venous thromboembolism: an update of the Vienna Prediction model. J Am Heart Assoc 2014; 3: e000467.

33. Marucchi M, Iorio A, Douketis JD, Eichinger S, Toosetti A, Baglin T, Cushman M, Palareti G, Poli D, Tait RC, Kyle PA. M, Palareti G, Poli D, Tait RC, Douketis J. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10: 1019–1025.

34. van Hylckama Vlieg A, Baglin CA, Luddington R, MacDonald S, Rosendaal FR, Baglin TP. The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THROMBUS study. J Thromb Haemost 2015; 13: 1642–1653.

35. Franco-Marone AJ, García Navarro MJ, Ortiz Sánchez J, Martin Díaz RM, Madroñal Cerezo E, De Arcas Arcáiz CL, Cabello Clozet N, Peralas Frail I, Gimeno García S, Montero Hernández C, Zapatera Gaviria A, Ruiz Giardini J. A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES). Eur J Intern Med 2016; 29: 59–64.

36. Franco-Marone AJ, Garcia Navarro MJ, Ortiz S, Ruiz Giardini J. Predicting recurrence after a first unprovoked venous thromboembolism: retrospective validation of the DAMOVES score. Eur J Intern Med 2017; 41: e15–e16.

37. Agno W, Donadini M. Breadth of complications of long-term oral anticoagu- lant care. Hematology Am Soc Hematol Educ Program 2018; 2018: 432–438.

38. Klok FA, Niemann C, Delles C, Hasselfuhr G, Konstantinides S, Lankeit M. Persistent recurrence of different bleeding prediction scores in patients with acute pulmonary embolism. Thromb Haemost 2016; 112: 312–320.

39. Riva N, Bellesini M, Di Minno MN, Mumoli N, Pomerio F, Franchini M, Fantani C, Lupoli B, Brandi B, Borrutta V, Bonfanti C, Agno W, Dentati F. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study. Thromb Haemost 2014; 112: 511–521.

40. Palareti G, Antonucci E, Mastroiacovo D, Agno W, Pergo V, Poli D, Testa S, Toosetti A, Prandoni P. The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism. J Thromb Haemost 2018; 16: 1994–2002.

41. Klok FA, Hosel V, Clemens A, Yoloi WW, Tille C, Schulman S, Lankeit M, Konstantinides SV. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation therapy. Eur Respir J 2016; 48: 1369–1376.

42. Becattini C, Agnelli G, Schenone A, Eichinger S, Buchneri E, Silingardi M, Bianchi M, Moia M, Agno W, Vandelli MR, Grandone E, Prandoni P. WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 365: 1959–1967.

43. Brighton TA, Eikelboom JW, Mann K, Mörk R, Gallus A, Ockelford P, Gibbes H, Hague W, Xavier D, Diaz R, Kirby A, Simes J. ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367: 1979–1987.

44. Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mörk R, Prandoni P, Brighton TA. INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism). Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 2014; 130: 1062–1071.
Diagnosis and management of acute deep vein thrombosis

65. Weitz JI, Lening AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P, Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017;376:1211–1222.

66. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Haemost 2016;14:13–14.

67. Prins MH, Lensing AWA, Prandoni P, Wells PS, Verhamme P, Beyer-Westendorf J, Bauersachs R, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Kakkar AK, van Bellen B, Pap AF, Homering M, Tamm M, Weitz JJ. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv 2018;2:788–796.

68. Prego V, Denas G, Zapparoli G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirlanduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerossa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018;132:1365–1371.

69. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raikob GE, Weitz JJ, Investigators P-E. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699–708.

70. Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, Crowther M. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2018;16:1289–1295.

71. Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, Asensio-Cruz M, Blasco-Cantó A, Mahe I, Chidiac J, Bertoletti L, Font C, Trujillo-Santos J, Peris M, Perez Ductor L, Rabinovich A, Kahn SR. The postthrombotic syndrome: current evidence and future challenges. Br J Haematol 2019;185:1666–1874.

72. Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol 2009;145:286–295.

73. Rabinovich A, Kahn SR. The post-thrombotic syndrome: current evidence and future challenges. J Thromb Haemost 2017;15:230–241.

74. Rabinovich A, Ducruet T, Kahn SR, SOX Trial Investigators. Development of a clinical prediction model for the postthrombotic syndrome in a prospective cohort of patients with proximal deep vein thrombosis. J Thromb Haemost 2018;16:262–270.

75. Amin EE, van Kuijk SM, Joore MA, Prandoni P, Ten Cate H, Ten Cate-Hoek AJ. Development and validation of a practical two-step prediction model and clinical risk score for post-thrombotic syndrome. Thromb Haemost 2018;118:1242–1249.

76. Mean M, Lmücher A, Altans A, Ajuszkiewicz J, Mazzolai L. Derivation and validation of a prediction model for risk stratification of post-thrombotic syndrome in elderly patients with a first deep vein thrombosis. Thromb Haemost 2018;118:1419–1427.

77. Wik HS, Enden TR, Ghanima W, Engeseth M, Kahn SR, Sandset PM. Diagnostic scales for the post-thrombotic syndrome. Thromb Res 2018;164:110–115.

78. Brandjes DP, Buller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, ten Cate JW. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997;349:759–762.

79. Prandoni P, Lensing AW, Prins MH, Frulla M, Marchioni A, Bernardi E, Tornmene D, Mosena L, Pagnan A, Giroldi A. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomised, controlled trial. Ann Intern Med 2004;141:249–256.

80. Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, Tagalakis V, Houlwen AH, Ducruet T, Holcroft C, John M, Solyamo S, Miron MJ, Yeo E, Smith R, Schulman S, Kass J, Keoran C, Chagnon I, Wong T, Demers C, Hanniah M, Kaatz S, Selby R, Rathbun S, Desmarais S, Opatrny L, Ortel TL, Ginsberg JS, SOX Trial Investigators. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014;383:880–888.

81. Avila ML, Montoya M, Lumia C, Marson A, Brandao LR, Tomlison G. Compression stockings to prevent post-thrombotic syndrome in adults, a Bayesian meta-analysis. Thromb Res 2019;182:20–26.

82. Mol GC, van de Ree MA, Klok FA, Tegelberg MJ, Sanders FB, Koppen S, de Weert O, Koster T, Hovens MM, Kaasjager HA, Brouwer RE, Kragten E, Schar CG, Spering W, Arnold WP, Bisma DH, Husman MV. One versus two years of elastic stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. BMJ 2016;353:i2691.

83. Weitz JI, Lensing AWA, Prins MH, Levi M, Beyer-Westendorf J, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Trajmovic M, Gabel M, Lam P, Wells PS, Prins MH. Recurrent venous thromboembolism and abnormal uterine bleeding with and without hormone contraception: a randomised, controlled trial. Blood 2016;127:1457–1465.

84. Stamm-SLB, Malmback CB, van de Ree MA. Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ 2015;351:h4847.
